Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Dabigatran etexilate generation I (Drug); Dabigatran etexilate generation II (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
The objective was to demonstrate the bioequivalence of capsules made from 2 different drug
product batches. The reference batch was representative of the current commercial drug
product and of the pivotal Phase III batches. The test batch was the drug product batch
intended for future commercial use.
Clinical Details
Official title: Bioequivalence of Two Different Generations of Drug Product of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: AUC0-infinity (area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity)Cmax (maximum measured concentration of total dabigatran in plasma)
Secondary outcome: AUC0-infinity (area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity)Cmax (maximum measured concentration of free dabigatran in plasma) AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) AUCt1-t2 (area under the concentration time curve of the analyte in plasma over the time interval t1 to t2 with t1 = 0 and t2 = 24, 48, 72 hours) tmax (time from dosing to the maximum concentration of the analyte in plasma) λz (terminal rate constant in plasma) t1/2 (terminal half-life of the analyte in plasma) MRTpo (mean residence time of the analyte in the body after oral administration) CL/F (apparent clearance of the analyte in the plasma after extravascular administration) Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Eligibility
Minimum age: 65 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion criteria:
1. Healthy males and females according to the following criteria: Based upon a complete
medical history, including the physical examination, vital signs (blood pressure,
pulse rate), 12-lead electrocardiogram, clinical laboratory tests
2. Age ≥60 and ≤85 years
3. Body mass index (BMI) ≥18. 5 and BMI ≤30. 0 kg/m2
4. Signed and dated written informed consent prior to admission to the study in
accordance with GCP and the local legislation
Exclusion criteria:
1. Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular,
metabolic, immunological or hormonal disorders
2. Clinically relevant surgery of gastrointestinal tract
3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
neurological disorders
4. Any relevant bleeding history
5. History of relevant orthostatic hypotension, fainting spells or blackouts
6. Chronic or relevant acute infections
7. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
to the trial as judged by the investigator
8. Intake of drugs with a long half-life (>24 hours) within at least one month or less
than 10 half-lives of the respective drug prior to administration or during the trial
9. Use of drugs which might reasonably influence the results of the trial based on the
knowledge at the time of protocol preparation within 10 days prior to administration
or during the trial
10. Participation in another trial with an investigational drug within four weeks prior
to administration or during the trial
11. Alcohol abuse (more than 60 g/day for men and more than 40 g/day for woman)
12. Drug abuse
13. Blood donation (more than 100 mL within four weeks prior to administration or during
the trial)
14. Excessive physical activities (within one week prior to administration or during the
trial)
15. Any laboratory value outside the reference range that is of clinical relevance
(especially hemoglobin and activated partial thromboplastin time) or positive drug or
virus screening
16. Planned surgeries within four weeks following the end-of study examination
17. Inability to understand the protocol requirements, instructions and study-related
restrictions, the nature, scope, and possible consequences of the study
18. Unlikely to comply with the protocol requirements, instructions and study-related
restrictions; e. g., uncooperative attitude, inability to return for follow-up visits,
and improbability of completing the study
19. Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist,
study coordinator, other staff or relative thereof directly involved in the conduct
of the study
20. Intake of medication, which influences the blood clotting, i. e., acetylsalicylic
acid, coumarin etc. within 10 days prior to administration
21. Vulnerable subjects (e. g. persons kept in detention)
22. Male subjects who do not agree to minimise the risk of female partners becoming
pregnant from the first dosing day until the completion of the post study medical
examination. Acceptable methods of contraception comprises barrier contraception and
a medically accepted contraceptive method for the female partner (intra-uterine
device with spermicide, hormonal contraceptive since at least two months)
Locations and Contacts
Additional Information
Starting date: May 2008
Last updated: June 20, 2014
|